<DOC>
	<DOCNO>NCT00245635</DOCNO>
	<brief_summary>This trial study effectiveness medication fluoxetine child adolescent age 16 young BDD qualify .</brief_summary>
	<brief_title>Fluoxetine Pediatric Body Dysmorphic Disorder</brief_title>
	<detailed_description>BDD usually begin childhood adolescence , treatment pediatric population investigate . Recent data suggest adult BDD may respond serotonin reuptake inhibitor ( SRIs ) fluoxetine ( Prozac ) . Preliminary finding case report suggest SRIs may also effective treatment BDD child adolescent . This study first large-scale , double-blind , placebo-controlled medication trial fluoxetine child adolescent BDD . Participants age 16 young . Participation trial last approximately 14 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Body Dysmorphic Disorders</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Male female child adolescent age 16 young BDD delusional variant present currently least 6 month prior study Ability communicate meaningfully investigator competent provide write assent Presence Schizophrenia Bipolar Disorder Recent suicide attempt suicidal ideation warrant hospitalization Previous allergic reaction fluoxetine History seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Body Dysmorphic Disorder</keyword>
	<keyword>BDD</keyword>
	<keyword>BDD treatment</keyword>
	<keyword>delusionality variant</keyword>
	<keyword>OCD</keyword>
</DOC>